Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b regimen of the ELEVATE study will be presented.The…
KOLKATA, India, May 26, 2026 /PRNewswire/ -- An elderly man in his sixties with multiple health complications, including Type 2 diabetes,…
This positive CHMP opinion is based on results from the Phase 3 BREAKWATER trial, which showed that encorafenib in combination…
Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X in patients with NCFB colonised with Pseudomonas aeruginosa (Pa)Secondary…
NEW WESTMINSTER, British Columbia, May 19, 2026 (GLOBE NEWSWIRE) -- A BC-led clinical research team is behind a study that…
LONDON, May 13, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in Ai-driven precision medicine, today announced a partnership…
Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of heavily pre-treated…
Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health…
Ann Arbor, MI, March 13, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational and educational purposes only and…
Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around…